[{"id":"242a00a6-2e7d-4b18-8a4a-57905c77b105","acronym":"Lung-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT05364645","created_at":"2022-05-06T18:55:15.353Z","updated_at":"2024-07-02T16:34:27.438Z","phase":"Phase 2","brief_title":"Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05364645 - Lung-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive","tags":["EGFR • KRAS • BRAF • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Retevmo (selpercatinib) • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 07/25/2022","start_date":" 07/25/2022","primary_txt":" Primary completion: 06/27/2023","primary_completion_date":" 06/27/2023","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2024-06-11"},{"id":"ba697a0c-0213-4400-8a69-554239875d35","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT04268550","created_at":"2021-01-18T14:26:41.644Z","updated_at":"2024-07-02T16:34:59.356Z","phase":"Phase 2","brief_title":"Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)","source_id_and_acronym":"NCT04268550 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive","tags":["EGFR • KRAS • BRAF • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 04/08/2020","start_date":" 04/08/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-06-04"},{"id":"499178b3-c7bc-4839-8508-0d08c3db9fb9","acronym":"POSEIDON","url":"https://clinicaltrials.gov/study/NCT04322591","created_at":"2021-01-18T14:26:42.526Z","updated_at":"2024-07-02T16:35:25.104Z","phase":"","brief_title":"Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial","source_id_and_acronym":"NCT04322591 - POSEIDON","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET positive","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET positive"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/24/2020","start_date":" 03/24/2020","primary_txt":" Primary completion: 12/24/2024","primary_completion_date":" 12/24/2024","study_txt":" Completion: 03/24/2025","study_completion_date":" 03/24/2025","last_update_posted":"2023-12-27"},{"id":"b02b627b-33be-4001-b108-f3ebe1518b61","acronym":"","url":"https://clinicaltrials.gov/study/NCT06031558","created_at":"2023-09-11T16:10:34.173Z","updated_at":"2024-07-02T16:35:36.237Z","phase":"Phase 3","brief_title":"Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC","source_id_and_acronym":"NCT06031558","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET positive","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SY-5007"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/20/2023","start_date":" 06/20/2023","primary_txt":" Primary completion: 09/20/2024","primary_completion_date":" 09/20/2024","study_txt":" Completion: 06/20/2026","study_completion_date":" 06/20/2026","last_update_posted":"2023-09-21"},{"id":"985ab4d5-37c9-4b6d-a5be-3f7a1acef6ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05278364","created_at":"2022-03-14T13:54:01.472Z","updated_at":"2024-07-02T16:35:50.793Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor","source_id_and_acronym":"NCT05278364","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" PD-L1 • RET","pipe":" | ","alterations":" RET fusion • RET mutation • RET positive","tags":["PD-L1 • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SY-5007"],"overall_status":"Recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 04/23/2021","start_date":" 04/23/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 02/10/2025","study_completion_date":" 02/10/2025","last_update_posted":"2023-04-12"},{"id":"3e8f92c9-751f-48a5-a600-1fa3142b37ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT02450123","created_at":"2021-01-18T11:44:48.235Z","updated_at":"2024-07-02T16:36:08.898Z","phase":"","brief_title":"Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors","source_id_and_acronym":"NCT02450123","lead_sponsor":"Samsung Medical Center","biomarkers":" RET • FGFR","pipe":" | ","alterations":" RET fusion • FGFR amplification • RET positive","tags":["RET • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • FGFR amplification • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 03/23/2016","start_date":" 03/23/2016","primary_txt":" Primary completion: 08/30/2019","primary_completion_date":" 08/30/2019","study_txt":" Completion: 11/05/2019","study_completion_date":" 11/05/2019","last_update_posted":"2022-06-15"},{"id":"c7ffedfa-b221-47a0-8188-045db5ae4afc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02691793","created_at":"2021-01-18T13:07:48.373Z","updated_at":"2024-07-02T16:36:08.891Z","phase":"Phase 4","brief_title":"Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors","source_id_and_acronym":"NCT02691793","lead_sponsor":"Samsung Medical Center","biomarkers":" RET • FGFR2","pipe":" | ","alterations":" RET fusion • FGFR2 mutation • FGFR2 fusion • FGFR mutation • RET positive","tags":["RET • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • FGFR2 mutation • FGFR2 fusion • FGFR mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 11/20/2017","start_date":" 11/20/2017","primary_txt":" Primary completion: 08/30/2019","primary_completion_date":" 08/30/2019","study_txt":" Completion: 11/19/2019","study_completion_date":" 11/19/2019","last_update_posted":"2022-06-15"},{"id":"28b971bf-ba9b-4dbc-a6e8-b8b36e9a25d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04697446","created_at":"2021-01-18T14:26:45.505Z","updated_at":"2024-07-02T16:36:26.703Z","phase":"","brief_title":"External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC","source_id_and_acronym":"NCT04697446","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET positive","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Gavreto (pralsetinib)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 279","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 10/31/2021","primary_completion_date":" 10/31/2021","study_txt":" Completion: 10/31/2021","study_completion_date":" 10/31/2021","last_update_posted":"2021-08-10"},{"id":"4082ae60-844c-4356-b0ed-58114e9bb5d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01877083","created_at":"2021-01-18T08:26:53.340Z","updated_at":"2024-07-02T16:36:57.011Z","phase":"Phase 2","brief_title":"Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung","source_id_and_acronym":"NCT01877083","lead_sponsor":"Eisai Inc.","biomarkers":" KRAS • ALK • RET • KIF5B • CCDC6","pipe":" | ","alterations":" RET positive","tags":["KRAS • ALK • RET • KIF5B • CCDC6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 04/05/2013","start_date":" 04/05/2013","primary_txt":" Primary completion: 02/03/2016","primary_completion_date":" 02/03/2016","study_txt":" Completion: 11/02/2017","study_completion_date":" 11/02/2017","last_update_posted":"2019-08-13"},{"id":"bf503f95-6c66-4ad1-a196-5504346e60d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03168074","created_at":"2021-01-18T15:37:12.749Z","updated_at":"2025-02-25T13:34:54.857Z","phase":"Phase 2","brief_title":"Phase II Study of Single Agent Lenvatinib","source_id_and_acronym":"NCT03168074","lead_sponsor":"National University Hospital, Singapore","biomarkers":" ER • RET","pipe":" | ","alterations":" ER positive • RET positive","tags":["ER • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 03/28/2017","start_date":" 03/28/2017","primary_txt":" Primary completion: 03/28/2021","primary_completion_date":" 03/28/2021","study_txt":" Completion: 03/28/2021","study_completion_date":" 03/28/2021","last_update_posted":"2017-06-16"}]